H
epatitis B virus (HBV) is an important cause of illness and death in Australia, with up to 218 000 Australians living with chronic infection. 1 Aboriginal and Torres Strait Islander people -with rates of chronic infection of 3.7% nationally compared with 0.9% in the general population 2 and higher prevalence in remote communities -are recognised as a priority population in Australia's fi rst National Hepatitis B Strategy, endorsed in 2010. 3 Aboriginal and Torres Strait Islander people experience a rate of liver cancer up to 10 times that of the non-Indigenous population 4 with an overall two-to-threefold increase in the rate of HBV-related liver cancer expected by 2017. 3 Although a highly effective vaccine is now available and has been offered universally for newborns since 2000, many of those born before universal vaccination remain susceptible, and are at risk of exposure, primarily through sexual contact, including young adults not reached by adolescent catch-up programs. [5] [6] [7] [8] While the likelihood of acquiring chronic hepatitis B infection and experiencing long-term complications is far greater when exposure takes place in infancy, exposed adolescents and adults can experience serious acute illness, with a proportion leading to chronicity. 9 An important strategy for the control of HBV is targeted testing of people at risk. Recent guidelines recommend that people at risk, including Aboriginal and Torres Strait Islander people, be offered hepatitis B surface antibody (HBsAb), hepatitis B surface antigen (HBsAg), and hepatitis B core antibody (HBcAb) testing. The exception is in pregnancy, where testing for HBsAg only is recommended to detect chronic infection. Screening for all three markers concurrently allows a distinction to be made between the presence of chronic HBV, immunity from vaccination or prior infection, and susceptibility to infection. 10, 11 In order to examine recent testing practice as well as the prevalence of markers of infection and susceptibility, we undertook a review of HBV serology testing patterns and positivity in patients attending four Aboriginal community controlled health services (ACCHS) Setting: Four Aboriginal community controlled health services.
Participants: All patients attending for a clinical visit were included in the study. Hepatitis B testing records were included if at least one serological test for HBV was done.
Main outcome measures:
Percentage of clinical patients tested for hepatitis B, compliance with guidelines and serological status.
Results: A total of 2959 people aged 15-54 years were screened for HBV, representing 17.2% of all people with a clinical visit in the study period. A total of 865 Aboriginal patients were tested concurrently for hepatitis B surface antigen (HBsAg), hepatitis B core antibody and hepatitis B surface antibody. Of those, 352 (40.7%) were susceptible to HBV infection (95% CI, 37.4%-43.9%) and 34 (3.9%) had either an acute or chronic infection indicated by a positive HBsAg result (95% CI, 2.6%-5.2%). In 329 women with antenatal screening, six (1.8%) returned a positive HBsAg result (95% CI, 0.37%-3.28%).
Conclusion:
A substantial proportion of patients tested were susceptible to HBV, with a high percentage potentially infectious compared with the general population. High levels of active infection and susceptibility to infection suggest many opportunities for transmission and indicate the potential benefi t of routine HBV testing and vaccination in this population. 
-5.9).
A lack of antibodies to HBV, through either vaccination or prior infection, was not related to age or sex.
A total of 572 women aged between 15 and 48 years seen at the services were pregnant, including 474 Aboriginal and Torres Strait Islander women aged 15-44 years, 329 of whom (69.4%) were tested for HBsAg with six positive results; a prevalence of 1.8% (95% CI, 0.37%-3.28%).
Discussion
The analyses reported are of a substantial sample of Aboriginal and Torres Strait Islander people tested for all three hepatitis B serological markers drawn from urban and regional ACCHS, and are the fi rst data of their kind available in this setting. In this study, about 40% of Aboriginal adolescents and adults remain susceptible to HBV infection. Potential infectiousness indicated by a positive HBsAg result was high at nearly 4%, but with signifi cant variation by age (Box 3 and Box 4). The high levels of active infection and susceptibility to HBV infection suggest many opportunities for transmission, primarily through sexual partnerships but also in close household contacts.
These results may not be representative of the clinic population as It is also important to note that a negative HBsAb result, as defi ned by a titre of < 10 mIU/mL, does not necessarily indicate the absence of vaccination, as titres decline to below this level in up to 50% of people receiving a full course of vaccination after less than a decade. 14,15 Protection appears to be maintained for at least two decades after vaccination in healthy individuals who achieved an initial response to vaccine. 14 Therefore, a proportion of the study sample defi ned serologically as "susceptible" may have been vaccinated.
Understanding HBV population prevalence can guide clinical service policy and practice regarding HBV testing, immunisation and health promotion. The retrospective data reported here indicate that a quarter of the patients who had some form of HBV testing had testing in accordance with recent guidelines, a high proportion when compared with previous reports in primary care 16 and one that is likely to increase as the guidelines become more widely adopted in clinical practice.
Australian vaccination guidelines recommend Aboriginal Torres Strait Islander people be offered testing for previous HBV infection and vaccination if non-immune. 17 There are jurisdictional inconsistencies in funding HBV vaccination in adult Aboriginal and Torres Strait Islander people who are found to be non-immune after testing, which may refl ect the heterogeneity of risk on the basis of ethnicity criteria alone. [18] [19] [20] [21] [22] [23] [24] [25] Increased focus on appropriate testing and a nationally consistent approach to vaccination that is designed to provide optimal benefi t for Aboriginal and Torres Strait Islander people at risk would assist in further reducing the burden of HBV infection in a population that has been substantially affected by its consequences. 
